during its scale-up phase. Commenting on his new role, Executive Chairman Andrew Tunks said, “Stuart has demonstrated ...

In this potentially valuable computational study, the authors conducted atomistic and coarse-grained simulations to probe the temperature-dependent phase behaviors of ELF3, a disordered component of ...

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...

Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

He is in charge of the protein product strategy ... hurdle is that CAR-T cells have to be individually manufactured for each ...

The fate of a massive new housing development adjacent to the M67 is set to be determined at a pivotal meeting next week.

While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will ...

TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 578 million ( USD 4.0 million1) in four projects for the ...